Shares of Lupin Ltd surged 2% to touch a day’s high of Rs 2,244.50 on 5th February after the company announced the launch of Topiramate extended-release capsules in the United States in 25 mg, 50 mg, 100 mg, and 200 mg strengths, following approval of its Abbreviated New Drug Application (ANDA) by the US FDA.

Lupin’s Topiramate extended-release capsules are bioequivalent to Trokendi XR of Supernus Pharmaceuticals. They are approved for treating partial-onset and primary generalised tonic-clonic seizures in patients aged six years and above.

The drug can also be used as add-on therapy for multiple seizure types, including those linked to Lennox-Gastaut syndrome. Additionally, it is used for preventing migraines in patients aged 12 years and older.

The US market for Topiramate extended-release capsules is estimated at $164 million annually. This figure is based on IQVIA MAT data for December 2025.

This week, Lupin announced two major developments across its businesses. These covered both innovation-led research and generic drug launches in the US.

The company entered a strategic collaboration with TB Alliance to support the development and future commercialisation of Telacebec. Telacebec is an investigational treatment for tuberculosis and other mycobacterial diseases.

While TB Alliance will lead clinical trials, Lupin will provide manufacturing, regulatory, and supply chain support. This will help expand patient access once the drug receives approval.

At 11:45 AM, shares of Lupin were trading 2.04% higher at Rs 2,239.90 on NSE.

Ready to invest like a pro? Tradz by EquityPandit equips you with 100+ Free tools and knowledge you need to succeed. Download the Tradz app and gain access to daily stock lists and insightful market analysis and much more!